X-111726910-C-G

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2

The NM_001099922.3(ALG13):​c.1831C>G​(p.Leu611Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000579 in 1,209,548 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 3 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L611F) has been classified as Likely benign.

Frequency

Genomes: š‘“ 0.000018 ( 0 hom., 0 hem., cov: 23)
Exomes š‘“: 0.0000046 ( 0 hom. 3 hem. )

Consequence

ALG13
NM_001099922.3 missense

Scores

1
16

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:1

Conservation

PhyloP100: 0.555

Publications

3 publications found
Variant links:
Genes affected
ALG13 (HGNC:30881): (ALG13 UDP-N-acetylglucosaminyltransferase subunit) The protein encoded by this gene is a subunit of a bipartite UDP-N-acetylglucosamine transferase. It heterodimerizes with asparagine-linked glycosylation 14 homolog to form a functional UDP-GlcNAc glycosyltransferase that catalyzes the second sugar addition of the highly conserved oligosaccharide precursor in endoplasmic reticulum N-linked glycosylation. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2009]
ALG13 Gene-Disease associations (from GenCC):
  • genetic developmental and epileptic encephalopathy
    Inheritance: XL Classification: DEFINITIVE Submitted by: ClinGen
  • developmental and epileptic encephalopathy, 36
    Inheritance: XL Classification: STRONG, SUPPORTIVE, LIMITED Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
  • non-syndromic X-linked intellectual disability
    Inheritance: XL Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.05623728).
BP6
Variant X-111726910-C-G is Benign according to our data. Variant chrX-111726910-C-G is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 389963.
BS2
High Hemizygotes in GnomAdExome4 at 3 XL gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ALG13NM_001099922.3 linkc.1831C>G p.Leu611Val missense_variant Exon 16 of 27 ENST00000394780.8 NP_001093392.1 Q9NP73-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ALG13ENST00000394780.8 linkc.1831C>G p.Leu611Val missense_variant Exon 16 of 27 2 NM_001099922.3 ENSP00000378260.3 Q9NP73-1

Frequencies

GnomAD3 genomes
AF:
0.0000179
AC:
2
AN:
111509
Hom.:
0
Cov.:
23
show subpopulations
Gnomad AFR
AF:
0.0000654
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000223
AC:
4
AN:
179198
AF XY:
0.0000149
show subpopulations
Gnomad AFR exome
AF:
0.000324
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000455
AC:
5
AN:
1098039
Hom.:
0
Cov.:
31
AF XY:
0.00000825
AC XY:
3
AN XY:
363479
show subpopulations
African (AFR)
AF:
0.000114
AC:
3
AN:
26400
American (AMR)
AF:
0.00
AC:
0
AN:
35207
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
19386
East Asian (EAS)
AF:
0.00
AC:
0
AN:
30204
South Asian (SAS)
AF:
0.00
AC:
0
AN:
54145
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
40523
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
4136
European-Non Finnish (NFE)
AF:
0.00000238
AC:
2
AN:
841960
Other (OTH)
AF:
0.00
AC:
0
AN:
46078
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.425
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000179
AC:
2
AN:
111509
Hom.:
0
Cov.:
23
AF XY:
0.00
AC XY:
0
AN XY:
33687
show subpopulations
āš ļø The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5.
African (AFR)
AF:
0.0000654
AC:
2
AN:
30572
American (AMR)
AF:
0.00
AC:
0
AN:
10527
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
2643
East Asian (EAS)
AF:
0.00
AC:
0
AN:
3553
South Asian (SAS)
AF:
0.00
AC:
0
AN:
2621
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
6037
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
234
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
53136
Other (OTH)
AF:
0.00
AC:
0
AN:
1502
āš ļø The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5. (p-value = 0.00000037155), which strongly suggests a high chance of mosaicism in these individuals.
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.325
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
4
Bravo
AF:
0.0000453
ExAC
AF:
0.0000415
AC:
5

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Inborn genetic diseases Uncertain:1
Nov 11, 2016
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.L611V variant (also known as c.1831C>G), located in coding exon 16 of the ALG13 gene, results from a C to G substitution at nucleotide position 1831. The leucine at codon 611 is replaced by valine, an amino acid with highly similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 5150 samples with coverage at this position. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. -

Developmental and epileptic encephalopathy, 36 Uncertain:1
Oct 17, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 611 of the ALG13 protein (p.Leu611Val). This variant is present in population databases (rs199505558, gnomAD 0.03%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with ALG13-related conditions. ClinVar contains an entry for this variant (Variation ID: 389963). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ALG13 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

not specified Benign:1
Oct 17, 2016
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.089
BayesDel_addAF
Benign
-0.56
T
BayesDel_noAF
Benign
-0.73
CADD
Benign
2.9
DANN
Benign
0.87
DEOGEN2
Benign
0.37
T;.;.;.;.;T
FATHMM_MKL
Benign
0.11
N
LIST_S2
Benign
0.64
T;T;.;T;.;T
M_CAP
Uncertain
0.12
D
MetaRNN
Benign
0.056
T;T;T;T;T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.4
L;.;.;.;.;.
PhyloP100
0.56
PrimateAI
Benign
0.24
T
PROVEAN
Benign
-1.4
N;.;N;.;.;.
REVEL
Benign
0.015
Sift
Benign
0.16
T;.;T;.;.;.
Sift4G
Benign
0.70
T;T;T;T;T;T
Polyphen
0.11
B;B;B;B;B;.
Vest4
0.16
MVP
0.28
MPC
0.18
ClinPred
0.0056
T
GERP RS
1.5
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.090
gMVP
0.22
Mutation Taster
=96/4
polymorphism

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs199505558; hg19: chrX-110970138; API